Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib pharmacogenetics in NSCLC
NL-OMON25881Recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Erasmus MC. Primary endpoints: Correlation of ABCB1, ABCG2, and CYP3A4 variants with CNS metastasis response in patients with baseline CNS metastases, CNS progression-free survival in patients with baseline CNS metastases and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON25881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25881.